Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) (NCT05925803)
A Multicenter, Randomized, Parallel-group, Double-blind,Two-arm Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared With Placebo in Male and Female Participants 18 to 70 Years of Age Inclusive With Systemic Sclerosis
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic sclerosis, either limited or diffuse cutaneous subsets, with a disease duration of less than 6 years from first non-Raynaud's phenomenon symptom.
Who can join: Review the eligibility criteria below.
Location: Research Site — Scottsdale, Arizona
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (150 Sites)
Showing the first 25 of 150 sites.
- Research Site — Scottsdale, Arizona
- Research Site — Chula Vista, California
- Research Site — Los Angeles, California
- Research Site — Orange, California
- Research Site — Aurora, Colorado
- Research Site — New Haven, Connecticut
- Research Site — Washington D.C., District of Columbia
- Research Site — Boca Raton, Florida
- Research Site — Fort Lauderdale, Florida
- Research Site — Gainesville, Florida
- Research Site — Jacksonville, Florida
- Research Site — Margate, Florida
- Research Site — South Miami, Florida
- Research Site — Tamarac, Florida
- Research Site — Chicago, Illinois
- Research Site — Kansas City, Kansas
- Research Site — New Orleans, Louisiana
- Research Site — Baltimore, Maryland
- Research Site — Ann Arbor, Michigan
- Research Site — Rochester, Minnesota
- Research Site — Babylon, New York
- Research Site — New York, New York
- Research Site — Cincinnati, Ohio
- Research Site — Pittsburgh, Pennsylvania
- Research Site — Allen, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Systemic Sclerosis
- KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis — Palo Alto, California
- Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial — Charleston, South Carolina
- A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis — Scottsdale, Arizona
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis — New York, New York
- Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis — Houston, Texas
Explore by condition: All Systemic Sclerosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.